Zimbabwe has rejected a significant US health deal valued at $367m (272 million pounds) spanning five years over Washington's insistence on confidential biological samples.
This move came to light after a official document dated December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the arrangement was "skewed".
An official spokesman later stated that the US was demanding access to health data for scientific study and commercial gain while refused to guarantee the benefits from future vaccines.
"We will now turn to the challenging and unfortunate process of winding down our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had furnished more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged continued negotiations to find a deal agreeable to all parties so the country's vital HIV programme can be sustained.
Wider Context
This development follows a comparable case in neighbouring Kenya, where a court halted a related deal with the US after legal challenges were raised about the safety of Kenyans' health data.
After resuming office recently, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
The agency had overseen assistance for the US government, but Trump stated its expenditure was "inefficient" and his government was pursuing government-to-government deals to enhance transparency and responsibility.
As per statements, Sixteen African countries have so far agreed to similar health pacts, representing over $18.3bn in committed funds.
Specifics of the Declined Agreement
This assistance for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration would have delivered extraordinary benefits for Zimbabwean communities, especially the 1.2 million presently receiving HIV treatment via American-funded initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"The proposal required Zimbabwe to provide its genetic material and health information over an extended period, with no equivalent promise of benefiting from any scientific breakthroughs – like new medicines or tests – that could result from that provided information," he stated.
"Effectively, our nation would provide the basic resources for medical research with no certainty that the end products would be accessible to our citizens should a new health crisis arise."
National Interest and Global Health
He also noted that the US's withdrawal from the global health body and its push of one-on-one deals were upending structures previously established through the global health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework created to manage future global health emergencies.
"This mechanism is designed to guarantee that when a nation contributes its data, the benefits – such as vaccines and treatments – are shared equitably, not commercialised exclusively by those with the capability to create them."
Zimbabwe's reservations over the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We encourage ongoing dialogue with our American counterparts on how subsequent co-operation might be structured in a manner that honours the sovereignty and dignity of both nations."
Medical Community Response
A leading public health body said it recognised the government's concerns, but recommended that talks need to persist considering much of the country's HIV programmes relied on foreign aid.
"Where specific concerns exist, including those relating to data governance or agreement terms, these can often be addressed via detailed discussion and mutually agreed protections," it added.
The halted deal emphasises the ongoing tensions between receiving vital foreign assistance and protecting national sovereignty in an increasingly interconnected world.